Grants for Small businesses - Federal

This funding opportunity provides financial support for organizations to implement innovative solutions that enhance resilience and disaster preparedness in vulnerable communities affected by climate change and natural disasters.

The FY24 Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY24 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s). However, it is not necessary to receive a development award in order to apply for a full consortium award in the future. For FY24, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. Detailed information on the FY24 Transformative Breast Cancer Consortium Award is available under a separate program announcement (HT942524BCRPTBCCA).The FY24 Transformative Breast Cancer Consortium Development Award provides support to: Develop the infrastructure of a multi-institutional research team inclusive of scientists, clinicians, and breast cancer advocates (e.g., building appropriate collaborations, outlining integration, research management, administrative management, and communication plans, and devising an intellectual property plan) Generate necessary preliminary data to serve as proof of concept or for project integration Acquire research resources Develop a framework of necessary statistical analysesBreast cancer consumer advocates must be active participants in the development and execution of the Transformative Breast Cancer Consortium Development Award.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Research involving human subjects and research involving human anatomical substances and data is permitted; however, clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Transformative Breast Cancer Consortium Development Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $0.16M to fund approximately one Transformative Breast Cancer Consortium Development Award application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports research projects that investigate the long-term impacts of disasters on healthcare systems serving vulnerable populations in the U.S., aiming to improve access and reduce health disparities.

SUMMARY INFORMATION Federal Awarding Agency Name: U.S. Department of Agriculture NRCS Notice of Funding Opportunity Title: Kentucky NRCS Agricultural Conservation Easement Program Wetland Reserve Easement (ACEP WRE) Acquisition Services Agreement Notice of Funding Opportunity Number: USDA-NRCS-KY-ACEP- 24-NOFO0001367 Assistance Listing: This program is listed in the Assistance Listings (previously referred to as the Catalog of Federal Financial Assistance) on Sam.gov under 10.931 Agricultural Conservation Easement Program, which can be found at: https://sam.gove/content/home. SAM is a web-based, government-wide application that collects, validates, stores, and disseminates business information about the federal government's trading partners in support of the contract awards, grants, and electronic payment processes. Notice of Funding Opportunity Summary The Natural Resources Conservation Service (NRCS) is seeking proposals to assist with due diligence for acquiring Agricultural Conservation Easement Program (ACEP) Wetland Reserve Easements (WRE), including contracting for title exams, updates, and closing services; boundary surveys; appraisals and cultural resource investigations. ACEP WRE provides funding for the purchase of conservation easements held by NRCS, and to restore, protect, and enhance wetlands on eligible land. Proposals are requested for consideration of cooperative agreements with a period of performance not to exceed five years. For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov. Key Dates Applicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on TBD. For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or support@grants.gov. Awarding agency staff cannot support applicants regarding Grants.gov accounts. For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility, or the merits of a specific proposal will not be addressed.

This funding opportunity provides financial support for research projects that evaluate effective strategies to prevent child sexual abuse and problematic sexual behavior among youth, particularly through community partnerships and addressing health equity.

Please see the full FOA in EERE Exchange. The research and development (R) activities to be funded under this FOA will support the government-wide approach to the climate crisis by driving the innovation that can lead to the deployment of clean energy technologies, which are critical for climate protection. Specifically, this FOA will fund innovative solar photovoltaics (PV) R that reduces the cost of PV modules, reduces carbon and energy intensity of PV manufacturing processes, and optimizes PV technology for new, specialized markets. SETOs PVRD program works to accelerate the deployment of solar energy technologies by funding innovative R in PV cell and module technologies, balance-of-system components, reliability tracing and tracking, metrology, and other key research questions in PV. To accelerate toward these deployment targets and augment SETOs ongoing PV research portfolio,12 this FOA will fund R on innovative cell- and minimodule-level technologies focused on three major goals: Enable cost reduction on an LCOE basis through development of durable, high-efficiency cell and module PV technology Identify pathways to reduce the carbon intensity and energy intensity of industrial processes required to fabricate PV cells and modules Increase technical viability of PV cells and modules tailored for emerging integrated PV sectors, such as building-integrated PV (BIPV) and vehicle-integrated PV. This FOA will fund innovative R projects that aim to advance the state of the art in various cell and module technologies to accomplish these goals of cost reduction, lower carbon intensity, and viability of dual-use markets. This FOA is separated into two topic areas: Photovoltaic Advances in Cell Efficiency, Reliability, and Supply Chain (PACERS): Applications in four PV supply chain, cell, and module technology spaces are of particular interest: low-carbon synthesis of metallurgical-grade silicon (MGS, here defined as silicon that is 98% pure as defined by the 5/5/3 standard)13 production, crystalline silicon (c-Si) PV, III-V PV, and organic PV (OPV). However, proposals for any industrial process, cell, or minimodule-level research that enables the goals of this FOA will be considered, excluding areas specified as not of interest in Section I.C., such as perovskite technology, which is addressed in other funding programs, and CdTe technology, which is addressed in Topic Area 2. Building Academic Capabilities in Cadmium Telluride: Applications describing advanced R projects requiring the procurement or upgrade of CdTe equipment are of interest. Proposals should detail work that will enhance fabrication, characterization, or analytical capabilities while also benefiting the larger CdTe PV research community.

The National Cancer Institute (NCI) intends to issue a notice of funding opportunity (NOFO) for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialists Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigator of research project grants. This Notice of Intent to Publish is being provided to allow sufficient time for applicants to develop strong applications. Applications are limited to four per institution per receipt date including new (A0) and resubmissions (A1). NCI-designated cancer center consortia are considered one institution. NCI seeks a broad representation of institutions for this award mechanism and may take this into account when making funding decisions. The NOFO is expected to be published in late summer 2024 with only one expected application due date of November 5, 2024.

The FY 2023-2024 CRISI program, managed by the Federal Railroad Administration (FRA), is designed to fund projects that improve the safety, efficiency, and reliability of railroad infrastructure. The program is open to various applicants, including states, rail carriers, and local governments, and it focuses on a broad array of project types such as safety enhancements, congestion reductions, upgrades to short-line or regional railroads, and the development of new or substantially improved intercity passenger rail corridors. The total funding available for this opportunity is approximately $2.478 billion. The application deadline is set for May 28, 2024, at 11:59 PM EST. Projects must not only improve infrastructure but also enhance safety protocols, integrate innovative technology, and support economic vitality.

The "Ocean Exploration Fiscal Year 2025 Funding Opportunity" grant is aimed at funding projects that explore unknown or poorly understood areas of the ocean or maritime heritage, with a focus on advancing our understanding of the ocean, improving genetic libraries for deep-sea species, and enhancing the identification and documentation of significant maritime heritage resources.

This competition provides funding for individuals and organizations to develop innovative energy storage technologies that address unique challenges in underserved communities and extreme climates.

The National Institute on Alcohol Abuse and Alcoholism ( NIAAA) intends to reissue RFA-AA-23-001, Specialized Alcohol Research Centers (P50, Clinical Trial Optional), by publishing a NOFO to solicit applications for a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol-related problems, and other health-related consequences across the lifespan. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Fall 2024. This NOFO will utilize the P50 activity code. Details of the planned NOFO are provided below.

This funding opportunity provides financial support to organizations implementing strategies to prevent diabetes and improve health equity for populations at risk, focusing on statewide, local, or multisectoral approaches.

trainer program to educate, train, and prepare jail and prison staff so they are equipped to appropriately interact with people in a carceral setting who have mental illness (MI) and intellectual and developmental disabilities (IDD). This training should be developed by an institution of higher education or non-profit, for profit or tribal in conjunction with health care and corrections professionals to ensure a multidisciplinary approach. The training must focus on understanding behavioral health, including MI and substance use disorders, IDD, developing empathy, navigating community resources, and de-escalation skills and practical application training of those skills in a trauma-informed manner for all staff working in prisons and jails. The centerpiece of this training must be a 40-hour CIT train-the-trainer program.

This grant provides funding for U.S.-based researchers, including advanced graduate students, to participate in Earth-based simulations that support the planning and execution of future lunar missions under the Artemis program.

This funding opportunity supports experienced researchers looking to expand their expertise or shift their career focus through advanced training and research experiences at various institutions.

This grant provides funding to non-profit organizations and other eligible entities to promote human rights and accountability in North Korea through innovative and inclusive programs.

This funding opportunity provides financial support to small businesses collaborating with academic or non-profit labs to develop and commercialize innovative technologies and treatments for arthritis, musculoskeletal, and skin diseases.

This program provides funding for research that explores the causes of housing affordability issues in the U.S. and helps shape effective policy solutions.

This funding opportunity provides financial support for U.S.-based researchers and institutions to develop innovative human models that simulate radiation injuries, aiming to improve understanding and treatment of radiation exposure effects.

This funding opportunity provides support for high-risk clinical trials focused on infectious, immunologic, and allergic diseases, encouraging innovative research that can lead to new treatments and therapies.